RLMD — Relmada Therapeutics Share News
0.000.00%
Last trade - 00:00- $350.94m
- $133.21m
Relmada Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Relmada Therapeutics Inc expected to post a loss of $1.45 a share - Earnings Preview
Brief: Point72 Asset Management LP Reports 7.3% Passive Stake In Relmada Therapeutics Inc As Of October 13 - SEC Filing
U.S. STOCKS ON THE MOVE-BeiGene, Avient, Reata
U.S. STOCKS ON THE MOVE-Netflix, BeiGene, Norfolk
U.S. STOCKS ON THE MOVE-Howard Hughes, Rocket Lab, Relmada Therapeutics
Jefferies downgrades Relmada Therapeutics after depression drug fails study
U.S. RESEARCH ROUNDUP-BlackRock, Emerson, Infosys
U.S. STOCKS ON THE MOVE-Under Armour, VectivBio, Morgan Stanley
U.S. STOCKS ON THE MOVE-Domino's Pizza, Biogen, Twitter
Relmada Therapeutics sinks 80% as depression therapy fails
Relmada's depression drug fails to meet late-stage study goal (updated)
Brief: Relmada Therapeutics Announces Top-Line Results From Phase 3 Reliance III Trial For Rel-1017 As A Monotherapy For The Treatment Of Major Depressive Disorder
Relmada Therapeutics' depression drug fails to meet late-stage goal
Brief: Relmada Therapeutics Expects To Report Top-Line Data From Reliance III Trial Early Next Quarter
U.S. STOCKS ON THE MOVE-Relmada, Entera Bio, Eli Lilly
Relmada rises after Guggenheim raises PT
Relmada Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Relmada Therapeutics Reports Qtrly Loss Per Share $1.33